---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-042223"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:49:01.499842+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AVTX stockholders approve reverse stock split with ratio up to 1:250

## Summary
- Reverse stock split approved: 34.7M for, 31.6M against, 0.8M abstain (54.8% of votes cast).
- Board will determine final ratio between 1:5 and 1:250; split intended to maintain Nasdaq listing.
- Annual meeting quorum was 34.88% (67.1M of 192.4M shares outstanding).
- All five director nominees elected; Ernst & Young ratified as auditor for FY2023.

## SEC filing metadata
- accession: 0001628280-23-042223
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/0001628280-23-042223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/avtx-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-042223
- JSON: https://secwatch.observer/filing/0001628280-23-042223.json
- Plain text: https://secwatch.observer/filing/0001628280-23-042223.txt

## Key facts
- Shareholder Votes
  Avalo Therapeutics, Inc. shareholders approved Approval of an Amendment to our Certificate of Incorporation to Effect a Reverse Stock Split at the 2023-12-20 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-12-20
  source text: Proposal 2: Approval of an Amendment to our Certificate of Incorporation to Effect a Reverse Stock Split
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/0001628280-23-042223-index.htm
- Shareholder Votes
  Avalo Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-20 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-20
  source text: Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/0001628280-23-042223-index.htm
- Shareholder Votes
  Avalo Therapeutics, Inc. shareholders approved Election of Directors at the 2023-12-20 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-12-20
  source text: Proposal 1: Election of Directors By the vote reflected below, the Company’s stockholders elected each of the following individuals to the Board to hold office until the 2024 Annual Meeting and until their respective successors are elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023042223/0001628280-23-042223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.